rDNA origin Articles

Denmark’s Novo Nordisk debuts Victoza in the USA, aiming for $1 billion global sales by 2015

17 February 2010

Brazil's type 2 diabetes drug market will grow to $834 million by 2013

7 December 2009

Ipsen reveals positive findings with rhGH and Increlex

16 September 2009

Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales

27 April 2009

Sanofi's Apidra SoloSTAR cleared in the USA

9 March 2009

FDA clears Sanofi's Apidra for children

3 November 2008

Lantus shows benefits over determir and NPH

15 September 2008

66% of Lantus patients meet ADA's 7% target

16 June 2008

Levemir comparable to glargine in control and DACON

16 June 2008

Lilly pulls out of inhaled insulin development

17 March 2008

CHMP recommends Lilly's Forsteo

3 March 2008

Pfizer announces Exubera job cuts; Wyeth may cut workforce 10%

4 February 2008

Pfizer's 3rd-qtr suffers due to charges for dropping Exubera, generic competition

29 October 2007

Pfizer's 1st-qtr profits tumble 17.5%

30 April 2007

No weight gain for "majority" on Levemir

16 April 2007

Merck KGaA posts 49% net profit rise for 2006, with revenues up 8.5%

12 March 2007

Levemir demonstrates safety and efficacy

7 February 2007

Exubera shows safety and efficacy

7 February 2007

Eli Lilly PAP approved, patients hit by Part D loophole

9 October 2006

Exubera use not complicated by respiratory infections

25 September 2006

Emerging diabetes management solutions boost European market

14 August 2006

Vaccines boost Sanofi-Aventis 1st-half but French/German reforms hit drug sales

7 August 2006

Pfizer sued by Novo for patent infringement

7 August 2006

Serono's net income up 8% in 2nd-qtr

31 July 2006

Merck/Novartis' DPP-4 inhibitors and Lilly's ruboxistaurin are stars of ADA 2006

19 June 2006

Good A1C control and less weight gain on Novo Nordisk's Levemir

13 June 2006

Insmed updates on IPLEX launch

13 June 2006

EC grants orphan status to Tercica's Increlex

12 June 2006

Tercica says its Increlex provides significant price advantage

12 June 2006

Tercica's Increlex gets EU OD status for primary IGFD

5 June 2006

Insmed launches Iplex in USA

29 May 2006

Preotact gets EU Marketing approval

1 May 2006

Serono ready for acquisition trial as it turns in a first-quarter profit

1 May 2006

NICE says inhaled insulin "too expensive" for UK, Pfizer appeals to health professionals

24 April 2006

US FDA "approvable letter" for NPS' Preos

20 March 2006

Sanofi-Aventis launches Apidra insulin in USA

13 March 2006

Lilly launches Humalog rapid insulin in USA

13 February 2006

Tercica launches Increlex in USA

9 January 2006

Tercica submits Increlex MAA

19 December 2005

Insmed shares soar on news of US OD designation for Iplex

19 December 2005

Tercica responds to citizen petition

5 September 2005

FDA OKs Tercica's Increlex for primary IGFD

5 September 2005

Insmed files Citizen Petition to block Tercica's Increlex

22 August 2005

Novo Nordisk debuts GlucaGen HypoKit

18 July 2005

Positive results for Sanofi-Aventis' Lantus

20 June 2005

Tercica moves to block Insmed growth drug in USA

6 June 2005

Priority review for Tercica's growth agent

9 May 2005

Genentech and Ipsen add to existing accord

28 March 2005

Savient and Teva launch TEV-TROPIN for pediatric growth hormone deficiency

21 February 2005

Novo Nordisk to appeal court's hGH patent rulings

13 September 2004

FDA clears new delivery device for Aventis' Lantus

23 August 2004

Genentech and Alkermes end sales of Nutropin Depot

7 June 2004

Aventis to see if Lantus reduces CVD risk

1 March 2004

Serono 2003 profits up 21.6%, beating forecasts; promises even more

9 February 2004

FDA OKs Serono's Zorbtive for SBS

8 December 2003

Serono's Serostim approved in USA for AIDS wasting

8 September 2003

Beaufour gets EU Ok for Nutropin AQ

24 March 2003

Eli Lilly 2nd-qtr sales decrease 9%

29 July 2002

Eli Lilly exceeds $1 billion investment in capital projects and jobs

13 May 2002

FDA clears Nutropin AQ Pen

29 April 2002

Net income down 22% at Lilly as Prozac decline continues to hit hard

22 April 2002

Novo's NovoLog receives US approval for use in pumps

7 January 2002

Sharp decline in third-quarter 2001 net income for Lilly as Prozac sales

19 October 2001

New drugs lift Lilly's 2nd qtr sales 16%

23 July 2001

New drugs lift Lilly's 2nd qtr sales 16%

20 July 2001

Schwarz sells back hormone rights

8 June 2001

Pharmacia acquires remainder of Sensus

8 March 2001

Novo and Pharmacia settle hGH dispute

14 November 2000

US approval for Novo Nordisk's Norditropin

21 June 2000

First disclosure of Aventis' early-stage R&D pipeline

23 May 2000

Aventis gains US approval for Lantus

27 April 2000

Novo Nordisk settles Lilly patent dispute

2 February 2000

Healthy full-year results for many US pharmaceutical companies

27 January 2000

$180M lawsuit bill hits Genentech earnings

21 January 2000

Genentech's Nutropin Depot approved in USA

29 December 1999

Genentech in patent dispute with University of California

14 October 1999

Roche reducing stake in Genentech

11 October 1999

Genentech sales rise thanks to Herceptin and Rituxan, takes $1.15 billion

14 July 1999

Novo files for hGH liquid form in USA

2 July 1999

Serono Canada's Serostim Approved In Canada

3 December 1998

FDA Approves Genentech's Nutropin AQ For Turner Syndrome

7 April 1997

Novo Gets Go-Ahead For hGH

19 March 1997

Lilly's Humatrope For Turner Syndrome

23 December 1996

Serostim Launched For Cachexia In USA

9 December 1996

Serono Labs' Saizen Approved In USA

21 October 1996

Showing 1-85 of 85 articles

Go to beginningPrevious
  • 1
NextGo to end